Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Black Diamond Therapeutics (BDTX) Invested Capital (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Invested Capital for 3 consecutive years, with $218.9 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Invested Capital fell 33.15% year-over-year to $218.9 million, compared with a TTM value of $218.9 million through Sep 2021, down 33.15%, and an annual FY2020 reading of $307.8 million, up 752.62% over the prior year.
  • Invested Capital was $218.9 million for Q3 2021 at Black Diamond Therapeutics, down from $251.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $356.2 million in Q1 2020 and bottomed at -$47.2 million in Q4 2019.
  • Average Invested Capital over 3 years is $177.1 million, with a median of $251.0 million recorded in 2021.
  • The sharpest move saw Invested Capital skyrocketed 1947.76% in 2020, then plummeted 33.15% in 2021.
  • Year by year, Invested Capital stood at -$47.2 million in 2019, then soared by 752.62% to $307.8 million in 2020, then decreased by 28.86% to $218.9 million in 2021.
  • Business Quant data shows Invested Capital for BDTX at $218.9 million in Q3 2021, $251.0 million in Q2 2021, and $280.8 million in Q1 2021.